Treatment and treatment considerations in a patient with advanced breast cancer and acute intermittent porphyria [3]

Acta Oncologica

Volumn 45, Issue 3, 2006, Pages 337-339

  Kristiansen, Charlotte ^a   Langkjer, Sven Tyge ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMPICILLIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GENTAMICIN; KETOBEMIDONE; LETROZOLE; METOPROLOL; MORPHINE; NAVELBINE; PACLITAXEL; PORPHOBILINOGEN; PORPHYRIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ADVANCED CANCER; BREAST CANCER; CASE REPORT; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERTENSION; INTRADUCTAL CARCINOMA; LETTER; PAIN; PORPHYRIA; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; BREAST NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PORPHYRIA, ACUTE INTERMITTENT;

EID: 33646390676     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500434697     Document Type: Letter

References (11)

1. Kauppinen R. Porphyrias. Lancet 2005;365:241-52.
2. Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol 1997;44:427-34.
3. Arbus MH. Relationship between porphyria and the use of antineoplastics. Am J Hosp Pharm 1981;38:631.
4. Palmieri C, Vigushin DM, Peters TJ. Managing malignant disease in patients with porphyria. QJM 2004;97:115-26.
5. Cochon AC, Aldonatti C, San Martin de Viale LC, Wainstok dC. Evaluation of the porphyrinogenic risk of antineoplastics. J Appl Toxicol 1997;17:171-7.
6. Schaffer M, Schaffer PM, Panzer M, Wilkowski R, Duhmke E. Porphyrias associated with malignant tumors: results of treatment with ionizing irradiation. Onkologie 2001;24:170-2.
7. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95.
8. Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria. A case report and review of the literature. Support Care Cancer 2001;9:465-6.
9. Scarlett JD, Corry J, Jeal PN. Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP). Aust N Z J Med 1995;25:742-3.
10. Samuels B, Bezwoda WR, Derman DP, Goss G. Chemotherapy in porphyria. S Afr Med J 1984;65:924-6.
11. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.